NCT04309578 2024-02-28
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Unknown
Clinical Trials
19 trialsNCT05964543 2023-07-28
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
QureBio Ltd.
Phase 1/2 Unknown
NCT04483726 2022-08-22
DIPLOMA
University Hospital, Montpellier
Phase NA Unknown
NCT02773524 2022-01-13
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
Phase 3 Unknown
NCT04699071 2021-10-21
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
National University Hospital, Singapore
Phase 2 Unknown
NCT02795650 2021-02-26
AVATAR
Hospital Universitario de Fuenlabrada
Phase 2 Unknown
NCT01703650 2020-10-08
Role of Perfusion CT in Pancreatic Cancer
Seoul National University Hospital
Unknown
NCT04202601 2019-12-19
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
Peking University
Phase 1/2 Unknown
NCT03636685 2018-08-17
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
ChineseAMS
Phase 1/2 Unknown
NCT02125240 2018-07-16
ICWIP
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT03402464 2018-01-18
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT02863471 2017-10-31
PanHIPEC
University Hospital Tuebingen
Phase 1/2 Unknown
NCT01665417 2017-02-08
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT02103257 2015-04-29
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT02194556 2014-07-18
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT01921699 2013-08-13
Macrophages Effect on Chemoresistance
Rambam Health Care Campus
Phase NA Unknown
NCT01837173 2013-04-23
ECLNI-MC
University Hospital, Gasthuisberg
Unknown
NCT01523015 2013-02-05
Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction
Medical University of Lublin
Phase 2/3 Unknown
NCT00751543 2010-06-29
The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy
National Taiwan University Hospital
Phase NA Unknown